Tag: metformin

Articles

• Triple negative breast cancer characteristics
• Type 2 diabetes increases breast cancer risk

News

05/06/19

Metformin reduces resistance to Adriamycin chemotherapy

10/08/17

Use of metformin linked to lower recurrence among older BC survivors

03/22/15

Type 2 diabetes is linked to higher breast cancer stage at diagnosis

11/09/14

Metformin inhibits metastasis of triple negative breast cancer cells

10/31/13

Poor glucose control could reduce metformin's anti-cancer benefits

12/13/11

Metformin improves survival of diabetic women with HER2+ BC

11/18/11

Metformin may increase the effectiveness of radiation treatment

Studies

• Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions Cite
  Sekar AP, Nurmala S, Matsuura E, Tan XW, Rahmasari R, Sauriasari R. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2024; 18 10.1177/11782234241240173
• Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect Cite
  Zhu L, Yang K, Ren Z, Yin D, Zhou Y. Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect. Translational Oncology. Elsevier BV; 2024; 44:101945 10.1016/j.tranon.2024.101945
• Antidiabetic Drugs in Breast Cancer Patients Cite
  Garczorz W, Kosowska A, Francuz T. Antidiabetic Drugs in Breast Cancer Patients. Cancers. MDPI AG; 2024; 16:299 10.3390/cancers16020299
• Combination of metformin and gallic acid induces autophagy and apoptosis in human breast cancer cells Cite
  Haghshenas M, Firouzabadi N, Akbarizadeh AR, Rashedinia M. Combination of metformin and gallic acid induces autophagy and apoptosis in human breast cancer cells. Research in Pharmaceutical Sciences. Medknow; 2023; 18:663-675 10.4103/1735-5362.389956
• Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial Cite
  Bakry HM, Mansour NO, ElKhodary TR, Soliman MM. Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial. Frontiers in Pharmacology. Frontiers Media SA; 2023; 14 10.3389/fphar.2023.1181312
• Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer Cite
  Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.23.00296
• Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study Cite
  Löfling LL, Støer NC, Andreassen BK, Ursin G, Botteri E. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01697-2
• Metformin Anti-Tumor Effect and Metabolic Reprogramming in Breast Cancer Cells Cite
  Alharthy F, Alamoudi AA, Alnouri A, Alkhuzaee A, Ajabnoor G, AlQriqri M, et al. Metformin Anti-Tumor Effect and Metabolic Reprogramming in Breast Cancer Cells. Journal of Biochemical Technology. Polaris; 2023; 14:70-79 10.51847/u62zz2npvj
• Metformin combined with glucose starvation synergistically suppress triple-negative breast cancer by enhanced unfolded protein response Cite
  Li Y, Zhang Q, Yang J, He W, Jiang Y, Chen Y, et al. Metformin combined with glucose starvation synergistically suppress triple-negative breast cancer by enhanced unfolded protein response. Biochemical and Biophysical Research Communications. Elsevier BV; 2023; 10.1016/j.bbrc.2023.07.029
• Targeting Breast Cancer in Diabetic Mice Using a Combination of Thymoquinone and Metformin Cite
  Talib WH, Aboulqassim NSS. Targeting Breast Cancer in Diabetic Mice Using a Combination of Thymoquinone and Metformin. The Natural Products Journal. Bentham Science Publishers Ltd.; 2023; 13 10.2174/2210315512666220615114025
• Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications Cite
  Bashraheel SS, Kheraldine H, Khalaf S, Moustafa AA. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. Biomedicine & Pharmacotherapy. Elsevier BV; 2023; 162:114676 10.1016/j.biopha.2023.114676
• Metformin and long non-coding RNAs in breast cancer Cite
  Gholami M, Klashami ZN, Ebrahimi P, Mahboobipour AA, Farid AS, Vahidi A, et al. Metformin and long non-coding RNAs in breast cancer. Journal of Translational Medicine. Springer Science and Business Media LLC; 2023; 21 10.1186/s12967-023-03909-x
• AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy Cite
  Zhang X, Jiang Q, Su Y, Bu L, Sun Z, Wu X, et al. AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-022-02127-4
• Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials Cite
  Bellerba F, Chatziioannou AC, Jasbi P, Robinot N, Keski-Rahkonen P, Trolat A, et al. Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. Journal of Translational Medicine. Springer Science and Business Media LLC; 2022; 20 10.1186/s12967-022-03809-6
• Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy Cite
  Arinno A, Maneechote C, Khuanjing T, Prathumsap N, Chunchai T, Arunsak B, et al. Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2023; 1869:166618 10.1016/j.bbadis.2022.166618
• Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes Cite
  Chikermane SG, Sharma M, Abughosh SM, Aparasu RR, Trivedi MV, Johnson ML. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06706-0
• Metformin and testosterone replacement therapy inversely associated with hormone‐associated cancers (prostate, colorectal and male breast cancers) among older White and Black men Cite
  Lopez DS, Malagaris I, Polychronopoulou E, Tsilidis KK, Milani SA, Kristen Peek M, et al. Metformin and testosterone replacement therapy inversely associated with hormone‐associated cancers (prostate, colorectal and male breast cancers) among older White and Black men. Clinical Endocrinology. Wiley; 2022; 10.1111/cen.14803
• Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks Cite
  Sorrenti V, Benedetti F, Buriani A, Fortinguerra S, Caudullo G, Davinelli S, et al. Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks. Pharmaceuticals. MDPI AG; 2022; 15:912 10.3390/ph15080912
• Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes Cite
  Vakili-Ghartavol R, Mehrabian A, Mirzavi F, Rezayat SM, Mashreghi M, Farhoudi L, et al. Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes. Journal of Pharmacy and Pharmacology. Oxford University Press (OUP); 2022; 10.1093/jpp/rgac048
• Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells Cite
  Scordamaglia D, Cirillo F, Talia M, Santolla MF, Rigiracciolo DC, Muglia L, et al. Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. Journal of Translational Medicine. Springer Science and Business Media LLC; 2022; 20 10.1186/s12967-022-03463-y
• Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer Cite
  Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA. American Medical Association (AMA); 2022; 327:1963 10.1001/jama.2022.6147
• The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial Cite
  Barakat HE, Hussein RRS, Elberry AA, Zaki MA, Ramadan ME. The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-11138-3
• Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer Cite
  Jiang Y, Qian T, Li S, Xie Y, Tao M. Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. Annals of Translational Medicine. AME Publishing Company; 2022; 10:366-366 10.21037/atm-22-795
• Metformin and Breast Cancer: Where Are We Now? Cite
  Cejuela M, Martin-Castillo B, Menendez JA, Pernas S. Metformin and Breast Cancer: Where Are We Now?. International Journal of Molecular Sciences. MDPI AG; 2022; 23:2705 10.3390/ijms23052705
• Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Cite
  Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP, et al. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. Gynecologic Oncology. Elsevier BV; 2022; 10.1016/j.ygyno.2022.01.022
• Replacement of hydrochloride in metformin hydrochloride with caprylic acid to investigate its effects on MCF-7 and MDA-MB-231 breast cancer cell lines Cite
  Mousavi-Koodehi B, Darzi L, Sadeghizadeh M, Najafi F, Forouzandeh-Moghdam M. Replacement of hydrochloride in metformin hydrochloride with caprylic acid to investigate its effects on MCF-7 and MDA-MB-231 breast cancer cell lines. Life Sciences. Elsevier BV; 2022;:120308 10.1016/j.lfs.2022.120308
• Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use Cite
  Acheampong T, Lee Argov EJ, Terry MB, Rodriguez CB, Agovino M, Wei Y, et al. Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use. Cancer Causes & Control. Springer Science and Business Media LLC; 2022; 10.1007/s10552-021-01530-1
• Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells Cite
  Tully E, Bharti S, Woo J, Bhujwalla Z, Gabrielson E. Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells. Cancer Biology & Therapy. Informa UK Limited; 2021;:1-8 10.1080/15384047.2021.1982599
• Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial Cite
  Alipour S, Rastad H, Saberi A, Faiz F, Maleki-Hajiagha A, Abedi M. Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial. DARU Journal of Pharmaceutical Sciences. Springer Science and Business Media LLC; 2021; 10.1007/s40199-021-00424-6
• Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs Cite
  Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell International. Springer Science and Business Media LLC; 2021; 21 10.1186/s12935-021-02202-5
• Impact of metformin on the therapeutic effect of radiotherapy Cite
  Agbele AT, Faromika OP, Awe OO, Amodu FR, Edaogbogun GO, Bello KA. Impact of metformin on the therapeutic effect of radiotherapy. Radiation Medicine and Protection. Elsevier BV; 2021; 2:17-22 10.1016/j.radmp.2020.12.002
• Adhesion and Stiffness of Detached Breast Cancer Cells In Vitro: Co-Treatment with Metformin and 2-Deoxy-d-glucose Induces Changes Related to Increased Metastatic Potential Cite
  Zemljič-Jokhadar Š, Kokot G, Pavlin M, Derganc J. Adhesion and Stiffness of Detached Breast Cancer Cells In Vitro: Co-Treatment with Metformin and 2-Deoxy-d-glucose Induces Changes Related to Increased Metastatic Potential. Biology. MDPI AG; 2021; 10:873 10.3390/biology10090873
• Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside? Cite
  Marini C, Cossu V, Bauckneht M, Lanfranchi F, Raffa S, Orengo AM, et al. Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?. Biomolecules. MDPI AG; 2021; 11:1231 10.3390/biom11081231
• The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32 Cite
  Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, et al. The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 113:192-198 10.1093/jnci/djaa082
• Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study Cite
  Pateliya B, Burade V, Goswami S. Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study. Naunyn-Schmiedeberg's Archives of Pharmacology. Springer Science and Business Media LLC; 2021; 10.1007/s00210-021-02104-3
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Hautakoski A, Marttila M, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-88488-x
• Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies Cite
  Farahi A, Abedini MR, Javdani H, Arzi L, Chamani E, Farhoudi R, et al. Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies. Molecular and Cellular Biochemistry. Springer Science and Business Media LLC; 2021; 10.1007/s11010-020-04043-8
• Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study Cite
  Feng J, Qin X. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study. Diabetes Research and Clinical Practice. Elsevier BV; 2021;:108755 10.1016/j.diabres.2021.108755
• A prospective study of type 2 diabetes, metformin use, and risk of breast cancer Cite
  Park Y, Bookwalter D, O'Brien K, Jackson C, Weinberg C, Sandler D. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Annals of Oncology. Elsevier BV; 2021; 10.1016/j.annonc.2020.12.008
• Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production Cite
  Mdkhana B, Zaher DM, Abdin SM, Omar HA. Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production. Phytomedicine. Elsevier BV; 2021;:153470 10.1016/j.phymed.2021.153470
• Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter Cite
  Singh SV, Chaube B, Mayengbam SS, Singh A, Malvi P, Mohammad N, et al. Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2020;:166011 10.1016/j.bbadis.2020.166011
• Metformin modulates oncogenic expression of HOTAIR gene via promoter methylation and reverses epithelial–mesenchymal transition in MDA‐MB‐231 cells Cite
  Golshan M, Khaleghi S, Shafiee SM, Valaee S, Ghanei Z, Jamshidizad A, et al. Metformin modulates oncogenic expression of HOTAIR gene via promoter methylation and reverses epithelial–mesenchymal transition in MDA‐MB‐231 cells. Journal of Cellular Biochemistry. Wiley; 2020; 10.1002/jcb.29867
• Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo Cite
  Pateliya B, Burade V, Goswami S. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo. European Journal of Pharmacology. Elsevier BV; 2020; 891:173725 10.1016/j.ejphar.2020.173725
• Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity Cite
  Dahmani Z, Addou-Klouche L, Gizard F, Dahou S, Messaoud A, Chahinez Djebri N, et al. Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0240982 10.1371/journal.pone.0240982
• Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer Cite
  Xue L, Chen F, Yue F, Camacho L, Kothapalli S, Wei G, et al. Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05927-5
• Use of metformin and aspirin is associated with delayed cancer incidence Cite
  Sung JJ, Ho JM, Lam AS, Yau ST, Tsoi KK. Use of metformin and aspirin is associated with delayed cancer incidence. Cancer Epidemiology. Elsevier BV; 2020; 69:101808 10.1016/j.canep.2020.101808
• Patterns of cell death induced by metformin in human MCF-7 breast cancer cells Cite
  Dias Lopes NM, Marinello PC, Sanches LJ, da Silva Brito WA, Lovo-Martins MI, Pinge-Filho P, et al. Patterns of cell death induced by metformin in human MCF-7 breast cancer cells. Pathology - Research and Practice. Elsevier BV; 2020; 216:153199 10.1016/j.prp.2020.153199
• Effects of metformin on adipose-derived stromal cell (ADSC) – Breast cancer cell lines interaction Cite
  Teufelsbauer M, Rath B, Plangger A, Staud C, Nanobashvili J, Huk I, et al. Effects of metformin on adipose-derived stromal cell (ADSC) – Breast cancer cell lines interaction. Life Sciences. Elsevier BV; 2020; 261:118371 10.1016/j.lfs.2020.118371
• Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis Cite
  Marinello PC, Panis C, Silva TN, Binato R, Abdelhay E, Rodrigues JA, et al. Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. Pathology - Research and Practice. Elsevier BV; 2020; 216:153135 10.1016/j.prp.2020.153135
• Influences of preoperative metformin on immunological factors in early breast cancer Cite
  Tsukioki T, Shien T, Tanaka T, Suzuki Y, Kajihara Y, Hatono M, et al. Influences of preoperative metformin on immunological factors in early breast cancer. Cancer Chemotherapy and Pharmacology. Springer Science and Business Media LLC; 2020; 86:55-63 10.1007/s00280-020-04092-2
• Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study Cite
  Sundelin EIO, al-Suliman N, Vahl P, Vendelbo M, Munk OL, Jakobsen S, et al. Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:107-113 10.1007/s10549-020-05621-6
• Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients Cite
  Tharakan S, Zimmerman B, Ru M, Blanter J, Cascetta K, Tiersten A. Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. Oncology. S. Karger AG; 2020; 98:589-592 10.1159/000506076
• The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes Cite
  Min W, Wang B, Guo A, Mao G, Zhao Y, Zhang S, et al. The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes. World Journal of Oncology. Elmer Press, Inc.; 2020; 11:23-32 10.14740/wjon1242
• Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response Cite
  Hassinger TE, Berger AC, Christopher A, Knisely AT, Mehaffey JH, Brenin DR, et al. Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. Journal of Surgical Research. Elsevier BV; 2020; 247:52-58 10.1016/j.jss.2019.10.043
• Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51 Cite
  Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, et al. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1204-2
• Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment Cite
  Dong S, Ruiz‐Calderon B, Rathinam R, Eastlack S, Maziveyi M, Alahari SK. Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment. International Journal of Cancer. Wiley; 2019; 146:2576-2587 10.1002/ijc.32690
• Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer Cite
  Chen H, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2019; 28:1802-1808 10.1158/1055-9965.epi-19-0291
• Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases Cite
  Mastroianni A, Ciniselli CM, Panella R, Macciotta A, Cavalleri A, Venturelli E, et al. Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases. Nutrients. MDPI AG; 2019; 11:1020 10.3390/nu11051020
• Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes Cite
  Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Scientific Reports. Springer Science and Business Media LLC; 2019; 9 10.1038/s41598-019-42357-w
• Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells Cite
  Sharma A, Bandyopadhayaya S, Chowdhury K, Sharma T, Maheshwari R, Das A, et al. Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells. PLOS ONE. Public Library of Science (PLoS); 2019; 14:e0209435 10.1371/journal.pone.0209435
• Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial Cite
  Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:433-442 10.1007/s10549-018-05070-2
• Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells Cite
  Schexnayder C, Broussard K, Onuaguluchi D, Poché A, Ismail M, McAtee L, et al. Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. International Journal of Molecular Sciences. MDPI AG; 2018; 19:3692 10.3390/ijms19113692
• Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer Cite
  Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-0974-2
• Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer Cite
  Alaswad RS W, SM E, HS S, AD T. Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. Journal of Oncology Translational Research. OMICS Publishing Group; 2018; 04 10.4172/2476-2261.1000129
• Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization Cite
  Wang J, Sun X, Ma Q, Fu G, Cong L, Zhang H, et al. Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. Journal of Cellular and Molecular Medicine. Wiley; 2018; 22:3825-3836 10.1111/jcmm.13655
• Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3 Cite
  Di Y, De Silva F, Krol ES, Alcorn J. Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3. Nutrition and Cancer. Informa UK Limited; 2018; 70:306-315 10.1080/01635581.2018.1421677
• Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes Cite
  Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Investigational New Drugs. Springer Science and Business Media LLC; 2018; 36:782-796 10.1007/s10637-018-0568-y
• Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression Cite
  Zhang J, Li G, Chen Y, Fang L, Guan C, Bai F, et al. Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression. Journal of Cancer. Ivyspring International Publisher; 2017; 8:1849-1864 10.7150/jca.19858
• Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer Cite
  Davies G, Lobanova L, Dawicki W, Groot G, Gordon JR, Bowen M, et al. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0187191 10.1371/journal.pone.0187191
• The Effects of Paclitaxel and Metformin and Combined Treatments on TLR Signaling Pathway on MDA-MB-231 Breast Cancer Cell Lines Cite
  Ozgul M, Uluer ET, Onal T, Akogullari D, Ozbilgin K, Inan S. The Effects of Paclitaxel and Metformin and Combined Treatments on TLR Signaling Pathway on MDA-MB-231 Breast Cancer Cell Lines. Proceedings. MDPI AG; 2017; 1:1016 10.3390/proceedings1101016
• Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis Cite
  Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI. Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Research. American Association for Cancer Research (AACR); 2017; 77:6033-6041 10.1158/0008-5472.can-17-0687
• Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway Cite
  El-Ashmawy NE, Khedr NF, El-Bahrawy HA, Abo Mansour HE. Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. Tumor Biology. SAGE Publications; 2017; 39:101042831769223 10.1177/1010428317692235
• Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32 Cite
  Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, et al. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 164:371-378 10.1007/s10549-017-4265-x
• Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells Cite
  Ariaans G, Jalving M, Vries EGEd, Jong Sd. Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer. Springer Science and Business Media LLC; 2017; 17 10.1186/s12885-017-3230-8
• Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Cite
  Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Fumagalli D, et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1421-1429 10.1200/jco.2016.69.7722
• Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice Cite
  Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice. Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2017; 36 10.1186/s13046-017-0498-0
• Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo Cite
  Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, et al. Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo. Cancer Prevention Research. American Association for Cancer Research (AACR); 2017; 10:198-207 10.1158/1940-6207.capr-16-0211-t
• Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women Cite
  Hong J, Jonsson Funk M, Buse JB, Henderson LM, Lund JL, Pate V, et al. Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology. Ovid Technologies (Wolters Kluwer Health); 2017; 28:446-454 10.1097/ede.0000000000000635
• Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis Cite
  Coyle C, Cafferty F, Vale C, Langley R. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology. Elsevier BV; 2016; 27:2184-2195 10.1093/annonc/mdw410
• Abstract 3470: Obesity and metformin alter progression of triple negative breast cancer Cite
  Camacho L, Xue L, Dobrolecki L, Hilsenbeck SG, Nagi C, Putluri N, et al. Abstract 3470: Obesity and metformin alter progression of triple negative breast cancer. Prevention Research. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-3470
• Impact of metformin on metastases in patients with breast cancer and type 2 diabetes Cite
  Jacob L, Kostev K, Rathmann W, Kalder M. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. Journal of Diabetes and its Complications. Elsevier BV; 2016; 30:1056-1059 10.1016/j.jdiacomp.2016.04.003
• Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study Cite
  Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:709-720 10.1007/s10552-016-0744-3
• Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort Cite
  Buschard K, Thomassen K, Lynge E, Vejborg I, Tjønneland A, von Euler-Chelpin M, et al. Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 28:13-21 10.1007/s10552-016-0829-z
• The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling Cite
  Scherbakov AM, Sorokin DV, Tatarskiy VV, Prokhorov NS, Semina SE, Berstein LM, et al. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. IUBMB Life. Wiley; 2016; 68:281-292 10.1002/iub.1481
• Metformin may protect nondiabetic breast cancer women from metastasis Cite
  EL-Haggar SM, El-Shitany NA, Mostafa MF, El-Bassiouny NA. Metformin may protect nondiabetic breast cancer women from metastasis. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2016; 33:339-357 10.1007/s10585-016-9782-1
• Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer Cite
  Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. Cell Cycle. Informa UK Limited; 2016; 15:1046-1059 10.1080/15384101.2016.1152432
• Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells Cite
  Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep18673
• p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells Cite
  Li P, Zhao M, Parris AB, Feng X, Yang X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochemical and Biophysical Research Communications. Elsevier BV; 2015; 464:1267-1274 10.1016/j.bbrc.2015.07.117
• The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes Cite
  Vissers PAJ, Cardwell CR, van de Poll-Franse LV, Young IS, Pouwer F, Murray LJ. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:427-437 10.1007/s10549-015-3331-5
• Abstract 1011: Metformin inhibits angiogenesis, local and metastatic growth of triple-negative breast cancer by targeting two classes of adipose tissue progenitors Cite
  Orecchioni S, Gregato G, Reggiani F, Mancuso P, Calleri A, Talarico G, et al. Abstract 1011: Metformin inhibits angiogenesis, local and metastatic growth of triple-negative breast cancer by targeting two classes of adipose tissue progenitors. Tumor Biology. American Association for Cancer Research; 2014; 10.1158/1538-7445.am2014-1011
• Mechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Both In Vitro and In Vivo Cite
  Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Both In Vitro and In Vivo. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e108444 10.1371/journal.pone.0108444
• Metformin-Induced Killing of Triple-Negative Breast Cancer Cells Is Mediated by Reduction in Fatty Acid Synthase via miRNA-193b Cite
  Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, et al. Metformin-Induced Killing of Triple-Negative Breast Cancer Cells Is Mediated by Reduction in Fatty Acid Synthase via miRNA-193b. Hormones and Cancer. Springer Science and Business Media LLC; 2014; 5:374-389 10.1007/s12672-014-0188-8
• The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: Implications for cancer therapy and prevention Cite
  Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: Implications for cancer therapy and prevention. Biochimica et Biophysica Acta (BBA) - General Subjects. Elsevier BV; 2014; 1840:1943-1957 10.1016/j.bbagen.2014.01.023
• The effect of metformin on apoptosis in a breast cancer presurgical trial Cite
  Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. British Journal of Cancer. Springer Science and Business Media LLC; 2013; 109:2792-2797 10.1038/bjc.2013.657
• Metformin reverses multidrug resistance and epithelial–mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells Cite
  Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z. Metformin reverses multidrug resistance and epithelial–mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Molecular and Cellular Biochemistry. Springer Science and Business Media LLC; 2013; 386:63-71 10.1007/s11010-013-1845-x
• Glucose promotes breast cancer aggression and reduces metformin efficacy Cite
  Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng X, Arnadottir SS, et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. Informa UK Limited; 2013; 12:3759-3769 10.4161/cc.26641
• Association Between Metformin Therapy and Mortality After Breast Cancer: A population-based study Cite
  Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association Between Metformin Therapy and Mortality After Breast Cancer: A population-based study. Diabetes Care. American Diabetes Association; 2013; 36:3018-3026 10.2337/dc12-2535
• Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth Cite
  Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2012; 110:972-977 10.1073/pnas.1221055110
• Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies Cite
  Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies. Metabolism. Elsevier BV; 2013; 62:922-934 10.1016/j.metabol.2013.01.014
• Racial Differences in the Association Between Night Shift Work and Melatonin Levels Among Women Cite
  Bhatti P, Mirick DK, Davis S. Racial Differences in the Association Between Night Shift Work and Melatonin Levels Among Women. American Journal of Epidemiology. Oxford University Press (OUP); 2013; 177:388-393 10.1093/aje/kws278
• Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes Cite
  Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 137:807-816 10.1007/s10549-012-2404-y
• Diabetes, Metformin, and Breast Cancer in Postmenopausal Women Cite
  Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2844-2852 10.1200/jco.2011.39.7505
• Effect of Different Doses of Metformin on Serum Testosterone and Insulin in Non-Diabetic Women With Breast Cancer: A Randomized Study Cite
  Campagnoli C, Pasanisi P, Abbà C, Ambroggio S, Biglia N, Brucato T, et al. Effect of Different Doses of Metformin on Serum Testosterone and Insulin in Non-Diabetic Women With Breast Cancer: A Randomized Study. Clinical Breast Cancer. Elsevier BV; 2012; 12:175-182 10.1016/j.clbc.2012.03.004
• Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial Cite
  Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2593-2600 10.1200/jco.2011.39.3769
• Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1 Cite
  Onken B, Driscoll M. Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS ONE. Public Library of Science (PLoS); 2010; 5:e8758 10.1371/journal.pone.0008758
• Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro Cite
  Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. Informa UK Limited; 2009; 8:909-915 10.4161/cc.8.6.7933
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) Cite
  Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®). Clinical and Translational Oncology. Springer Science and Business Media LLC; 2009; 11:455-459 10.1007/s12094-009-0384-0
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer Cite
  He X, Esteva F, Ensor J, Hortobagyi G, Lee M, Yeung SJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:1771-1780 10.1093/annonc/mdr534
• Abstract C74: Eradicating cancer stem cells by targeting mTOR pathway with metformin. Cite
  Park HJ, Lee H, Williams B, Song CW. Abstract C74: Eradicating cancer stem cells by targeting mTOR pathway with metformin.. mTOR / PI3-Kinase. American Association for Cancer Research; 2011; 10.1158/1535-7163.targ-11-c74
• Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer Cite
  Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. Wiley; 2011; 118:1202-1211 10.1002/cncr.26439
• Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions Cite
  Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. Informa UK Limited; 2011; 10:2959-2966 10.4161/cc.10.17.16359
• The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells Cite
  Menendez . The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncology Reports. Spandidos Publications; 2010; 25 10.3892/or_00001052
• Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy Cite
  Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 123:333-344 10.1007/s10549-009-0647-z
• The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Cite
  Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:355-364 10.1007/s10549-010-0924-x
• Abstract 72: Metformin enhances tumor regression and reduces tumor burden in a preclinical paradigm modeling obesity's impact on postmenopausal breast cancer Cite
  Giles ED, Anderson SM, Schedin PJ, Thor AD, Johnson GC, Hedman KJ, et al. Abstract 72: Metformin enhances tumor regression and reduces tumor burden in a preclinical paradigm modeling obesity's impact on postmenopausal breast cancer. Cellular and Molecular Biology. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-72
• Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission Cite
  Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research. American Association for Cancer Research (AACR); 2009; 69:7507-7511 10.1158/0008-5472.can-09-2994
• Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer Cite
  Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:3297-3302 10.1200/jco.2009.19.6410